Dechra Pharmaceuticals In Tri-Solfen Deal, Ups Medical Ethics Stake
Mon, 8th Feb 2021 08:41
(Alliance News) -Â Dechra Pharmaceuticals PLC on Monday said it has secured the rights to market Tri-Solfen in Australia and New Zealand, and has acquired a further 1.5% stake in Medical Ethics Pty Ltd for AUD32.5 million, equivalent to around GBP18.1 million.
Under the deal, Dechra will acquire the marketing authorisations and enter a long term licensing agreement with Animal Ethics Pty Ltd. This will provide Dechra with exclusive rights to sell and market Animal Ethic's product, Tri-Solfen, which is already registered for sheep and cattle and is sold in Australia and New Zealand with current annual sales of AUD9.1 million.